Madrigal Pharmaceuticals Statistics
Share Statistics
Madrigal Pharmaceuticals has 22.2M
shares outstanding. The number of shares has increased by 3.61%
in one year.
| Shares Outstanding | 22.2M |
| Shares Change (YoY) | 3.61% |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 20,904 |
| FTD / Avg. Volume | 5.79% |
Short Selling Information
The latest short interest is 4.1M, so 18.49% of the outstanding
shares have been sold short.
| Short Interest | 4.1M |
| Short % of Shares Out | 18.49% |
| Short % of Float | 21.43% |
| Short Ratio (days to cover) | 11.43 |
Valuation Ratios
The PE ratio is -14.09 and the forward
PE ratio is -863.1.
Madrigal Pharmaceuticals's PEG ratio is
-1.47.
| PE Ratio | -14.09 |
| Forward PE | -863.1 |
| PS Ratio | 36.44 |
| Forward PS | 1.6 |
| PB Ratio | 8.7 |
| P/FCF Ratio | -14.36 |
| PEG Ratio | -1.47 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Madrigal Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.1,
with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.1 |
| Quick Ratio | 5.9 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | -0.27 |
| Debt / FCF | -0.26 |
| Interest Coverage | -33.94 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $341,160.98 |
| Profits Per Employee | $-882,371.21 |
| Employee Count | 528 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.18 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 21.54% in the
last 52 weeks. The beta is -0.92, so Madrigal Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -0.92 |
| 52-Week Price Change | 21.54% |
| 50-Day Moving Average | 313.1 |
| 200-Day Moving Average | 292.62 |
| Relative Strength Index (RSI) | 34.82 |
| Average Volume (20 Days) | 361,078 |
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M
and earned -465.89M
in profits. Earnings per share was -21.9.
| Revenue | 180.13M |
| Gross Profit | 173.9M |
| Operating Income | -497.88M |
| Net Income | -465.89M |
| EBITDA | -450.13M |
| EBIT | -451.22M |
| Earnings Per Share (EPS) | -21.9 |
Full Income StatementBalance Sheet
The company has 100.02M in cash and 119.57M in
debt, giving a net cash position of -19.55M.
| Cash & Cash Equivalents | 100.02M |
| Total Debt | 119.57M |
| Net Cash | -19.55M |
| Retained Earnings | -1.8B |
| Total Assets | 996.63M |
| Working Capital | 820.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -455.57M
and capital expenditures -1.46M, giving a free cash flow of -457.03M.
| Operating Cash Flow | -455.57M |
| Capital Expenditures | -1.46M |
| Free Cash Flow | -457.03M |
| FCF Per Share | -21.48 |
Full Cash Flow StatementMargins
Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.
| Gross Margin | 96.54% |
| Operating Margin | -276.39% |
| Pretax Margin | -258.64% |
| Profit Margin | -258.64% |
| EBITDA Margin | -249.88% |
| EBIT Margin | -276.39% |
| FCF Margin | -253.72% |
